Printer Friendly

CTI BioPharma to Present at 27th Annual Piper Jaffray Healthcare Conference.

SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015, at 12:00 p.m. EST/6:00 p.m. CET in New York.

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Contacts: Monique Greer +1 206-272-4343 mgreer@ctibiopharma.com

Ed Bell +1 206-272-4345 ebell@ctibiopharma.com

Logo - http://photos.prnewswire.com/prnh/20140529/92480

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-27th-annual-piper-jaffray-healthcare-conference-300183582.html

SOURCE CTI BioPharma Corp.

COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Conference news
Date:Nov 24, 2015
Words:335
Previous Article:Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolled.
Next Article:Boeing, EVA Airways Finalize Taiwan's Largest Ever Commercial Airplane Purchase.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters